Skip to content
Updates
WORKSPACE
Help & feedback

Built for Ontario pharmacy.

News & updates

Pharmacy news

RSS feed

Ontario & Canada

Practice Desk

Last month · 20 updates

20 updates in the last month

  2. CPSO Board Approves Changes to Safer Supply Prescribing Expectations

    Implications for pharmacies dispensing safer supply medication The College of Physicians and Surgeons of Ontario (CPSO) has approved amendments to...

    Source: OCP News & Announcements

  3. Safe and effective health products for Canadians: New authorizations between July and September 2026

    Canadians expect timely access to safe and effective drugs and medical devices. Health Canada is providing a quarterly update on the steps the department is taking to make its regulatory processes more modern and efficient, while maintaining high standards for safety, efficacy…

    Source: Health Canada — News Releases

  4. Drugs and medical devices authorized, July 1 to September 30, 2026

    From July 1 to September 30, 2026, Health Canada approved 16 new drug submissions (14 pharmaceuticals, 2 biologics) and 540 new medical devices, including 27 Class IV medical devices, which present the greatest potential risk. During this period, Health Canada also approved 30…

    Source: Health Canada — News Releases

  5. Flintstones Complete Multivitamins and Minerals: Recalled from wholesalers (Distribution Error)

    Customer-returned products were inadvertently reintroduced into saleable inventory and distributed to the wholesale level.

    Source: Drug Recalls & Safety Alerts (Recalls-rappels Canada)

  6. FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development

    The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases.

    Source: FDA — Press announcements (drug approvals)

  14. Billing

  16. FDA Approves First Treatment for MCT8 Deficiency

    The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on…

    Source: FDA — Press announcements (drug approvals)

  18. Billing

  20. Billing

Archive (109)Show

Older updates stay here for reference.

  1. FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A

    The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.

    Source: FDA — Press announcements (drug approvals)

  5. FDA Grants Accelerated Approval to a New Breast Cancer Treatment

    The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new treatments to patients who need them.

    Source: FDA — Press announcements (drug approvals)

  6. FDA Approves First Drug to Treat Alexander Disease

    The U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients.

    Source: FDA — Press announcements (drug approvals)

  7. FDA Issues Emergency Use Authorization for Drugs to Prevent and Treat New World Screwworm in Dogs and Cats

    The U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Capstar (nitenpyram) tablets and revised the EUA for Nitenpyram Tablets, the generic version of Capstar

    Source: FDA — Press announcements (drug approvals)

  10. FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

    The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.

    Source: FDA — Press announcements (drug approvals)

  12. Billing

  13. FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

    The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults.

    Source: FDA — Press announcements (drug approvals)

  14. FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in Cattle

    FDA issues Emergency Use Authorization (EUA) for Bimectin (ivermectin) injection for the prevention of New World screwworm (NWS) infestations (myiasis) in cattle when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound.

    Source: FDA — Press announcements (drug approvals)

  18. FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

    The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.

    Source: FDA — Press announcements (drug approvals)

  26. Supreme Court Reaffirms that Methods of Medical Treatment Are Not Patentable in Canada

    The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences. L’article Supreme Court Reaffirms that…

    Source: Canadian Generic Pharmaceutical Association — News

  28. Billing

  29. CGPA Calls for Participation of Generic and Biosimilar Medicines Industries in Implementation of Pharmaceutical and Life Sciences Task Force Report Recommendations

    The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences. L’article CGPA Calls for Participation of…

    Source: Canadian Generic Pharmaceutical Association — News

  49. The pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association extend agreement on pricing initiative for generic drugs

    The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences. L’article The pan-Canadian Pharmaceutical…

    Source: Canadian Generic Pharmaceutical Association — News

  53. Scope

    Nine new minor ailments pharmacists can prescribe for as of July 1, 2026

    Effective July 1, 2026, Ontario pharmacists and interns can assess and prescribe for nine more minor ailments (calluses/corns, dandruff, dry eye, head lice, jock itch, mild headache, nasal congestion, ringworm, warts), bringing the program to 28 conditions. Update assessment workflows and remember the legal duty to notify the patient's primary care provider.

    Source: Ontario College of Pharmacists — Minor Ailments Expansion

  55. Billing

    Ontario discontinues publicly funded COVID-19 PCR testing in pharmacies, effective June 1, 2026

    Effective June 1, 2026, Ontario's pharmacy COVID-19 PCR testing program is discontinued and its associated PINs are deactivated, so those claims no longer adjudicate. PCR testing supplies can no longer be ordered through the PPE Supply Portal as of May 15, 2026. Free rapid antigen tests remain available, and PCR testing continues via primary care, high-risk community settings, and hospitals. Retain pharmacy COVID-19 testing claim records for at least 10 years.

    Source: Ontario MOH — Executive Officer Notice (May 20, 2026)

  56. Billing

  57. Billing

    ODB minor-ailment service funding set at $19 in-person / $15 virtual ahead of the July 1, 2026 expansion

    The Ontario MOH Executive Officer Notice "Update to Funding for Minor Ailment Services in Ontario Pharmacies" (published 2026-05-19, effective July 1, 2026) confirms a pharmacy receives $19 for an in-person assessment or $15 for a virtual assessment per valid claim under a Table 1 PIN, regardless of whether a prescription is issued. It replaces the prior notice effective Nov 18, 2024, and the nine new ailments are billable under this same fee structure.

    Source: Ontario MOH — EO Notice: Minor Ailment Services Funding (Effective July 1, 2026)

  58. Billing

  60. Scope

    Pharmacists gain 6 publicly funded vaccines — 3 administrable now, public funding for all six begins July 1, 2026

    Effective May 11, 2026, Ontario added pertussis, tetanus, and diphtheria to Schedule 3 of O. Reg. 256/24 — pharmacists and interns with registered injection training and valid CPR/first aid may now administer these three. Starting July 1, 2026, administration of all six (tetanus, pertussis, diphtheria, pneumococcal, RSV, herpes zoster/shingles) becomes publicly funded for eligible Ontarians. Note: May 11 grants administration authority for three; July 1 is when public funding for all six begins.

    Source: Ontario College of Pharmacists — Scope of Practice Changes

  61. Scope

    Pharmacy technicians authorized to administer Schedule 3 vaccines; CPR/First Aid mandatory by March 31, 2027

    Pharmacy technicians and intern technicians will be able to administer all Schedule 3 vaccines under O. Reg. 256/24, expanding immunization staffing beyond pharmacists. Phased rollout: effective July 1, 2026, a technician may administer once they register their injection training with the College (without yet holding CPR/First Aid); CPR/First Aid certification becomes mandatory to continue injecting as of March 31, 2027. Owners should verify a technician's registered injection training now, and CPR/First Aid by the 2027 deadline.

    Source: Ontario College of Pharmacists — Scope of Practice Changes

  62. Billing

  63. Billing

  64. Billing

    Seniors Co-Payment Program income thresholds rise for 2026/27 (effective Aug 1, 2026)

    Effective Aug 1, 2026, Ontario raised the income cutoffs for the Seniors Co-Payment Program (waives the $100 ODB deductible, caps copay at $2/Rx vs. up to $6.11). The individual net income threshold rises from $25,000 to $25,480 and the couple threshold from $41,500 to $42,290, so more seniors may qualify; thresholds will now track the Ontario CPI annually. Already-enrolled seniors confirmed by CRA need do nothing; others can apply at forms.ontariodrugbenefit.ca.

    Source: Ontario MOH — Seniors Co-Payment Program Q&A (Executive Officer Notice)

  65. Billing

  67. Formulary / EO

    Femyso designated interchangeable (OFI) with Mifegymiso and publicly funded, effective April 30, 2026

    Effective April 30, 2026, Femyso (mifepristone/misoprostol, DIN 02560569) is an Off-Formulary Interchangeable product with Mifegymiso (DIN 02444038) under DIDFA and eligible for public funding. Pharmacies may dispense and claim either for any Ontarian with a valid health card and prescription, billing PIN 09858391 (Mifegymiso) or 09858392 (Femyso) at $256.25 per valid claim, using intervention code PS (plus ML and Carrier ID "S" for non-ODB patients). Confirm the correct DIN/PIN before substituting.

    Source: Ontario MOH — EO Notice: Mifepristone/Misoprostol Reimbursement (April 23, 2026)

  68. Billing

  70. Billing

  72. Estrogen transdermal patches in intermittent shortage as MHT demand rises

    Increased demand for menopausal hormone therapy is causing intermittent supply gaps in some estrogen transdermal patches in Canada. Per CPhA this is not a Tier 3 shortage and alternatives remain available — patches from other manufacturers, plus transdermal gels, vaginal creams, and tablets. Expect substitution requests and patient questions at the counter; the Canadian Menopause Society's systemic MHT equivalency table helps when switching formulations.

    Source: CPhA — Managing current drug shortages (Menopausal Hormone Therapy)

  74. Cyclophosphamide injection in Tier 3 shortage across all Canadian suppliers

    Health Canada declared a Tier 3 (most serious) shortage of cyclophosphamide for injection on Feb 20, 2026, with all three Canadian suppliers (Baxter, Sterimax, Andone) short across multiple vial sizes, mitigated via exceptional importation of foreign-labelled product and expected to continue into spring 2026. As a hospital/oncology-administered injectable, community pharmacies are unlikely to dispense it directly but may field patient questions about oncology/autoimmune supply.

    Source: Health Canada — Tier 3 drug shortages

  76. MAR-Amlodipine 5 mg recalled — some bottles contain midodrine instead

    Marcan Pharmaceuticals recalled two lots of MAR-Amlodipine 5 mg (DIN 02371715, lots 2472021 and 2472021A, exp. July 2027) because some bottles may contain midodrine 2.5 mg tablets instead of amlodipine. Visually verify tablets before dispensing and pull affected stock — correct amlodipine is white/off-white, 8-sided, marked "210"/"5"; the wrong midodrine is round, white, marked "M2". The mix-up can cause dangerous blood-pressure changes, fainting, and organ damage.

    Source: Health Canada — Recalls & Safety Alerts

  77. Billing

  80. Dimethyl fumarate (Tecfidera and generics): serious GI-event risk to be added to Canadian monographs

    A Health Canada Summary Safety Review found a possible link between dimethyl fumarate and serious gastrointestinal events (perforation, ulceration, hemorrhage, obstruction) based on 22 international cases. Health Canada will work with manufacturers to update the Canadian product monograph for all DMF products (Tecfidera and generics, for relapsing-remitting MS). Counselling point: advise MS patients to recognize and promptly report serious GI symptoms. Published in the January 2026 Health Product InfoWatch.

    Source: Health Canada — Summary Safety Review: Dimethyl Fumarate (Jan 2026 InfoWatch)

  81. Do you manage dental pain with opioids?

    In January 2026, the Therapeutics Initiative mailed the early release of the individual prescribing Portrait entitled “Do you manage dental pain with opioids?” to dentists in British Columbia (use the DOWNLOAD button above to access...

    Source: Therapeutics Initiative — Therapeutics Letter (UBC)

  85. Avoid antibiotics for self-limited viral infections

    References Costelloe C, Metcalfe C, Lovering A, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010; 340:c2096. DOI: 10.1136/bmj.c2096 Bell BG, Schellevis F,...

    Source: Therapeutics Initiative — Therapeutics Letter (UBC)

  86. Formulary / EO

    Biosimilar transition window for tocilizumab, omalizumab, and aflibercept closes May 28, 2026

    Under Ontario's biosimilars policy, ODB recipients on originator Eylea (aflibercept), Actemra (tocilizumab), and Xolair (omalizumab) must switch to a biosimilar within the transition period to keep ODB coverage. The window runs Nov 28, 2025 to May 28, 2026 for aflibercept, and to the earlier of May 28, 2026 or the patient's EAP approval expiry for tocilizumab and omalizumab (unless an exception applies). Ensure affected patients are switched and prescriptions reflect the biosimilar.

    Source: Ontario MOH — Biosimilars

  87. FreeStyle Libre 3 Plus sensors recalled for falsely low glucose readings

    Health Canada posted Abbott's recall of certain FreeStyle Libre 3 Plus Sensor Kits (Model 78791-01) that may report incorrect low glucose readings, risking dangerous treatment decisions for diabetes patients. Pharmacies that sell/dispense these CGM sensors should flag affected stock and direct patients to freestylecheck.com to check serial numbers, stop use, and request a replacement.

    Source: Health Canada — Recalls & Safety Alerts (RA-81314)

  88. Billing

  89. Billing

  90. Statement from the Canadian Generic Pharmaceutical Association (CGPA) on the 2025 Federal Budget

    The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences. L’article Statement from the Canadian…

    Source: Canadian Generic Pharmaceutical Association — News

  91. Porcine (animal-sourced) insulin supply ends in Canada; imported Hypurin bridges only to May 31, 2026

    Wockhardt UK, the sole remaining supplier of porcine insulin, discontinued its Canadian vial supply. Health Canada authorized exceptional, temporary importation of UK-authorized Hypurin Porcine Neutral (interchangeable with Hypurin Regular Insulin, Pork), but that imported stock expires May 31, 2026. After that, the ~60–100 Canadians who rely on animal-sourced insulin will need to transition to human insulin and analogues — a conversation community pharmacists will help manage.

    Source: Health Canada — Animal-sourced insulin discontinuation notice

  92. Managing dental pain: Patient information sheet

    In January 2026, the Therapeutics Initiative mailed the individual prescribing Portrait entitled “Do you manage dental pain with opioids?” to dentists in British Columbia. This Portrait was accompanied by the Therapeutics Letter “Pharmacological management of...

    Source: Therapeutics Initiative — Therapeutics Letter (UBC)

  93. Billing

  94. CGPA and Biosimilars Canada welcome the Government of Quebec’s initiative to improve access to cost-saving medicines

    The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences. L’article CGPA and Biosimilars Canada…

    Source: Canadian Generic Pharmaceutical Association — News

  95. Billing

  96. Billing

  97. Billing

  98. Billing

  99. Billing

  100. Billing

  101. Billing

  102. Billing

    Executive Officer Notice: Biosimilar Policy Update July 2025

    Ontario Public Drug Programs notice (PDF) for pharmacies and dispensers.

    Source: Executive Officer (EO) Communications

  103. Ipratropium nebules under Tier 3 shortage, supply gaps projected into 2026

    Health Canada declared a Tier 3 shortage of ipratropium bromide nebules, with both Teva (Sterinebs) and Pharmascience (PMS-Ipratropium) affected by manufacturing disruptions; intermittent shortages and supply gaps are projected to last into 2026. Pharmacists dispensing for COPD/asthma nebulizer patients should expect ongoing constraints and substitute to ipratropium HFA pressurized metered-dose inhalers (with spacer) where clinically appropriate.

    Source: CPhA & medSask — Ipratropium Bromide Shortage

  104. Billing

  105. National pharmaceutical associations join forces in identifying solutions for drug shortages

    The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences. L’article National pharmaceutical…

    Source: Canadian Generic Pharmaceutical Association — News

  106. Michel Robidoux of Sandoz Canada Elected Chair of Canadian Generic Pharmaceutical Association

    The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences. L’article Michel Robidoux of Sandoz Canada…

    Source: Canadian Generic Pharmaceutical Association — News

  107. Generic and Biosimilar Medicines Industries Welcome Ontario Government’s Investment in Next Phase of Life Sciences Strategy

    The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences. L’article Generic and Biosimilar Medicines…

    Source: Canadian Generic Pharmaceutical Association — News

  108. CGPA and Biosimilars Canada Statement on Proposed Pharmacare Legislation

    The generic and biosimilar medicines industries will need to learn more about the Government of Canada’s approach to implementation, and consult with key stakeholders, to help ensure that a transition to this program would maximize the use of cost-saving generic and biosimilar…

    Source: Canadian Generic Pharmaceutical Association — News

Research & global news

Reading Shelf

Last 45 days · 52 items

  1. Global

    Allergies and Autoimmune Disease: Shared Immune Dysfunction?

    Medscape Medical News

    Research shows both disease types may arise from shared inflammatory pathways, genetic susceptibilities, and potential environmental contributors. Medscape Medical News

  2. Global

    MASH: Efruxifermin Linked to Sustained Fibrosis Response

    Medscape Medical News

    A bivalent FGF21 analogue, efruxifermin, is linked to an improved fibrosis response in patients with metabolic dysfunction-associated steatohepatitis and fibrosis or compensated cirrhosis. Medscape Medical News

  3. Global

    Unions Call Proposed 2.4% Doctors’ Pay Rise ‘Derisory’

    Medscape Medical News

    The government says it can fund the uplift without trade-offs, but the BMA and UNISON warn it risks driving staff from the NHS. Medscape News UK

  4. Global

    Hospital Glucose Meter Recalled Due to Barcode Scan Problem

    Medscape Medical News

    Nova Biomedical alerted affected customers recommending removal of StatStrip Glucose Hospital Meters pending a software fix. Medscape Medical News

  5. Global

    ACOG Updates Guidance on Menopause Symptom Management

    Medscape Medical News

    The new guideline addresses sleep and mood in addition to vasomotor symptoms and includes the most current data on newer menopause medications. Medscape Medical News

  6. Global

    Underwater ESD Speeds Colorectal Resection

    Medscape Medical News

    Filling the colon with water rather than gas during ESD improved visibility and procedural efficiency in a randomized Italian trial. Medscape Medical News

  7. Global

    MHRA Authorises ApoC3 Inhibitor for Rare Lipid Disorder

    Medscape Medical News

    Plozasiran, given by injection every 3 months, cut triglycerides by a median of around 80% in a trial of 75 adults. Medscape News UK

  8. Global

    Phenotyping Helps in Managing Difficult-to-Treat RA

    Medscape Medical News

    When faced with difficult-to-treat rheumatoid arthritis, the key in most cases is separating patients into inflammatory and noninflammatory phenotypes. Medscape Medical News

  9. Global

    NR4A2: a next-generation drug target orchestrating dynamic gene regulation and protein interactions

    Drug Discovery Today

    Drug Discovery Today · Rashmi Arora, Simran Gambhir, Anshu Bhardwaj et al.

  10. Global

    Patient access to cell and gene therapies in Europe: stakeholder perspectives on impeding factors across the medicine lifecycle

    Drug Discovery Today

    Drug Discovery Today · Christine C. van Hattem, Jurriaan Gort, Renske M.T. ten Ham et al.

  11. Canada

    Bioequivalence of budesonide inhalation suspension with and without activated charcoal in healthy Chinese subjects: two randomized four-period crossover trials

    Journal of Pharmacy & Pharmaceutical Sciences

    Demonstrating bioequivalence for locally acting inhaled products is challenging because systemic exposure may reflect both pulmonary absorption and gastrointestinal absorption of the swallowed fraction. Activated charcoal can suppress gastrointestinal uptake and may help…

  12. Canada

    Integrated computational screening and biochemical validation identify natural small molecules targeting Aβ aggregation and dissociation

    Journal of Pharmacy & Pharmaceutical Sciences

    Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β (Aβ), a pathological hallmark implicated in disease onset and progression. Aβ undergoes self-assembly from monomers into soluble oligomers, protofibrils, insoluble fibrils, and extracellular plaques. Our…

  13. Canada

    Diabesity: an old term, a modern challenge — multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes

    Journal of Pharmacy & Pharmaceutical Sciences

    Type 2 diabetes mellitus (T2DM) and obesity are closely interconnected but heterogeneous conditions in which treatment response, safety, body weight, glycemic control, and long-term clinical outcomes vary substantially between individuals. This narrative review evaluates…

  14. Global

    Fluoroquinolone Prescribing in Primary Care: Patient Safety, Antimicrobial Stewardship and Forensic Implications Under the Italian Framework—A Narrative Review

    Pharmacy (MDPI)

    Fluoroquinolones remain widely prescribed in primary care although regulators have restricted their use because of rare but serious, potentially disabling and irreversible adverse reactions. This narrative review, based on a PubMed search (2008–2026) and regulatory and Italian…

  15. Global

    Pharmacists’ Perspectives on Their University Education: A Comparative Study of Graduates from Northern Sweden

    Pharmacy (MDPI)

    This study evaluated educational satisfaction among pharmacists who graduated from Umeå University’s online pharmacy programs between 2019 and 2023, including the potential impact of the COVID-19 pandemic. Satisfaction levels were compared with those reported by graduates from…

  16. Global

    AI-integrated iPSC multi-omics: advancing phenotype discovery and drug target identification in rare diseases

    Drug Discovery Today

    Drug Discovery Today · Soukaina Amniouel, Zeenat A. Shyr, Ewy A. Mathé et al.

  17. Global

    Advancing a drug-development program is not the same as de-risking it

    Drug Discovery Today

    Drug Discovery Today · Mileidys Perez-Alea

  18. Global

    AI-Powered Personal Tutors as a Scalable Solution to the 2-Sigma Problem in Pharmacy Education

    Pharmacy (MDPI)

    Background: The “2 Sigma Problem”, where individualized tutoring outperforms conventional instruction by two standard deviations, remains a persistent challenge in large-enrollment pharmacy courses. Generative AI tutors, constrained to instructor-verified content, offer a…

  19. Global

  20. Global

    Pharmacist and Pharmacy Student Vaccination Authority: An International Survey of Pharmacy Educators

    Pharmacy (MDPI)

    Background/Objectives: Pharmacists’ vaccination authority has expanded globally over the past four decades, but the scope of practice, meaning which vaccination activities pharmacists are legally authorised to perform, varies substantially by country. Pharmacy student authority…

  21. Global

    The role and mechanism of heat shock proteins in the development of pulmonary arterial hypertension

    Drug Discovery Today

    Drug Discovery Today · Honglin Xiang, Bin Zeng, Shiwei Wu et al.

  22. Global

    A Narrative Review of Medicare Part D Medication Therapy Management Program Design Challenges and the Development of an Evidence-Informed MTM Benefit Program for a Large Self-Insured Employer

    Pharmacy (MDPI)

    The Medicare Part D Medication Therapy Management (MTM) program has several well-documented challenges, including restrictive eligibility criteria, low patient engagement, and difficulties integrating MTM services into pharmacy workflows and broader healthcare teams. These…

  23. Canada

    A mechanistic quantitative systems pharmacology framework for glucosamine sulfate in knee osteoarthritis: linking exposure, cartilage biology, and clinical outcomes

    Journal of Pharmacy & Pharmaceutical Sciences

    Glucosamine is widely used for osteoarthritis management, yet clinical trial results remain controversial, despite robust preclinical anti-inflammatory effects that fail to translate consistently into clinical benefit. We hypothesized that a mechanistic QSP framework could…

  24. Global

    Blockbuster drugs and forecast accuracy: How sponsor type is associated with commercial success of FDA-approved medicines

    Drug Discovery Today

    Drug Discovery Today · Michael R. Myers, Michael Kinch, Kevin Murgas et al.

  25. Global

    Systematic review of EU and US product labels containing real world data in support of efficacy claims

    Drug Discovery Today

    Drug Discovery Today · Ana Glória Cruz, Chiara Rancan, Elisa Cerruti et al.

  26. Global

    Comparative Short-Term Clinical Events Associated with Molnupiravir and Ensitrelvir for COVID-19: A Retrospective Cohort Study Using Community Pharmacy Records in Japan

    Pharmacy (MDPI)

    Molnupiravir and ensitrelvir are widely used for outpatient coronavirus disease 2019 treatment; however, real-world safety comparisons remain limited. This retrospective cohort study evaluated acute clinical event risks over a 29-day follow-up using community pharmacy records…

  27. Canada

    The pharmaceutical applications of palm kernel oil: innovations in dermatological therapies

    Journal of Pharmacy & Pharmaceutical Sciences

    Dermatological problems of the skin, hair or nails are considered one of the most cutaneous complaints and form around 30% of all visits to dermatologists. Recent treatments have been focused on exploring natural agents as alternatives for antibiotic-free treatments. Palm kernel…

  28. Global

    Exploring Artificial Intelligence-Generated Feedback for Pharmacy Students

    Pharmacy (MDPI)

    Background: The integration of artificial intelligence (AI) into educational environments is accelerating, with growing interest in its potential to enhance learning outcomes. This pilot study aimed to assess student perceptions regarding the quality and educational impact of…

  29. Global

    Diethylene glycol monoethyl ether as an alternative solvent for mRNA-LNP manufacture

    Journal of Pharmacy and Pharmacology

    To evaluate diethylene glycol monoethyl ether (DEGEE) as an alternative organic solvent to ethanol for mRNA lipid nanoparticle (LNP) manufacture. LNPs composed of distearoyl phosphatidylcholine, cholesterol, a PEGylated lipid and one of four ionizable lipids (SM-102, ALC-0315…

  30. Global

    Vaccine Dispensing Through Private Community Pharmacies in Costa Rica: A National Descriptive Analysis

    Pharmacy (MDPI)

    Background: Pharmacist involvement in immunization has expanded as a strategy to improve access to vaccines. In Costa Rica, private community pharmacies operate under a regulatory framework for vaccination services, yet evidence on private-market vaccine dispensing remains…

  31. Canada

    Carbapenem-based versus non-carbapenem therapy for hospital-acquired and ventilator-associated pneumonia in a resource-limited setting: a retrospective cohort study of clinical outcomes

    Journal of Pharmacy & Pharmaceutical Sciences

    Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are major causes of in-hospital mortality and antimicrobial resistance (AMR), particularly in low- and middle-income countries (LMICs). Carbapenems are commonly used due to their broad-spectrum activity…

  32. Global

    Integrating community pharmacies into clinical research: lessons learned from the RAPID IMMUNE TEST study

    International Journal of Pharmacy Practice

    International Journal of Pharmacy Practice · Andrew Turner, Alastair D Hay, Jonathan Campbell et al.

  33. Global

    QingGanJianPi oral solution ameliorates hyperlipidemia by facilitating crosstalk between multiple active metabolites and the PPARα-LXRα axis

    Journal of Pharmacy and Pharmacology

    QingGanJianPi oral solution (QGJP), a traditional Chinese patent medicine, exhibits lipid-lowering and hepatoprotective effects. This study aimed to elucidate the mechanisms by which QGJP promotes lipid and cholesterol efflux. Drug efficacy was evaluated in HFD-mice. Serum…

  34. Global

    Induction of Nrf2 activity by Daucus carota subsp. maximus : bioassay-guided isolation of chrysoeriol, luteolin 7- O -glucoside and eugenin as active compounds

    Journal of Pharmacy and Pharmacology

    To investigate the Nrf2 activity-inducing property of Daucus carota subsp. maximus and to isolate the bioactive compounds responsible for this. The cell viability (MTT) assay was performed using the AREc32 cell line to determine non-cytotoxic concentrations of the test samples.…

  35. Global

    Pharmacist contribution in rare diseases

    International Journal of Pharmacy Practice

    Rare diseases (RDs) present major challenges in diagnosis, treatment access, and care coordination. Pharmacists are increasingly recognized as important contributors in the management of patients with RDs. The aim of this study was to assess pharmacist contributions in RD…

  36. Global

    Pharmacists at the frontline: a qualitative investigation of the acceptability and feasibility of an ethical framework for preventing opioid-related harm in pharmacy practice

    International Journal of Pharmacy Practice

    To evaluate the acceptability and feasibility of a proposed ethical framework that describes pharmacists’ responsibilities when dispensing opioids. Qualitative methods were used to assess the views of pharmacists regarding the proposed framework. Registered pharmacists in…

  37. Global

    Exploring influences on intravenous-to-oral antibiotic switching: a qualitative interview study across healthcare professions

    International Journal of Pharmacy Practice

    Intravenous antibiotics are often continued longer than necessary leading to prolonged admission and increased infection risk. Existing research has reported barriers to IV-to-oral switch (IVOS) predominantly from a physician’s perspective, leaving gaps in understanding how…

  38. Canada

    Availability, utilization, and factors associated with professional pharmacy services in community pharmacies in Saudi Arabia: a cross-sectional study

    Journal of Pharmacy & Pharmaceutical Sciences

    Community pharmacists are increasingly expected to provide patient-centered clinical and public health services beyond traditional medication dispensing. However, the availability and utilization of these services in Saudi community pharmacies remain insufficiently…

  39. Global

    How community pharmacies can raise uterine cancer awareness among women from ethnic minority populations

    International Journal of Pharmacy Practice

    Community pharmacies are a potential route to reach underserved groups due to their locations and staff, who often reflect the diversity of the populations they serve. This study aimed to explore the potential for a uterine cancer awareness campaign encouraging earlier…

  40. Global

    When exceptions blur into the rule: toward an operational framework for exceptional drug access in Québec University hospitals

    Journal of Pharmaceutical Health Services Research

    Journal of Pharmaceutical Health Services Research · Denis Lebel, Nicole Déry, Marc Simard et al.

  41. Global

    Beyond dispensing metrics: are we overlooking structural risk accumulation in community pharmacy?

    International Journal of Pharmacy Practice

    International Journal of Pharmacy Practice · Ammar Abdulrahman Jairoun, Sabaa S Al-Hemyari, Moyad Shahwan et al.

  42. Global

    “The right person at the right time”: Regulatory and advocacy perspectives on collaboration of pharmacists and physiotherapists in primary care in Nova Scotia, Canada: A multi-methods study

    Journal of Pharmaceutical Health Services Research

    Interprofessional collaboration (IPC) is increasingly recognized as a critical strategy to strengthen primary care systems. In Nova Scotia, pharmacists and physiotherapists are two underutilized healthcare professionals who could work collaboratively to improve access to timely…

  43. Global

    Simulating workplace legal scenarios: preparing students through Objective Structured Clinical Examination-based training

    International Journal of Pharmacy Practice

    The aim of this study was to evaluate whether Objective Structured Clinical Examinations (OSCEs) are a viable assessment tool for testing pharmacy legal concepts, and to compare performance across OSCE and written assessments while exploring student and examiner perspectives. A…

  44. Global

    Return on investment and financial sustainability of pharmacy automation systems in healthcare: a systematic review

    Journal of Pharmaceutical Health Services Research

    This systematic review aims to evaluate the return on investment (ROI) and financial sustainability of pharmacy automation systems in healthcare settings. PubMed, Scopus, ScienceDirect, and Google Scholar were searched for peer-reviewed studies, with the search updated through 1…

  45. Global

    Care setting-associated variation in generic drug utilization across therapeutic classes in Japan: a cross-sectional analysis of nationwide prescription data

    Journal of Pharmaceutical Health Services Research

    Although generic drug utilization has exceeded 80% nationally in Japan, variation remains across therapeutic classes and prescribing environments. This study aimed to describe generic drug utilization across selected therapeutic classes and care settings using nationwide…

  46. Canada

    Effects of music elements on mycophenolate glucuronidation in rat liver microsomes

    Journal of Pharmacy & Pharmaceutical Sciences

    Mycophenolic acid (MPA), a first-line immunosuppressant for preventing transplant organ rejection, exhibits substantial inter- and intra-individual pharmacokinetic variability. We hypothesized that music elements (tempo, rhythm, and harmony) can affect the formation of MPA…

  47. Global

    Clove oil-derived β-caryophyllene carried in a self-nanoemulsifying drug delivery system improves adjuvant-induced arthritis in rats

    Journal of Pharmacy and Pharmacology

    β-Caryophyllene (β-Cary) exhibits anti-inflammatory and antioxidant activities. It can be obtained from clove oil, which is rich in eugenol; following eugenol removal, β-Cary can be isolated as the major constituent. However, the high lipophilicity of β-Cary limits its oral…

  48. Global

    Dual Notch-1 pathway regulation mitigates glial activation and preserves myelin integrity: neuroprotective and anticonvulsant actions of pentoxifylline in PTZ kindling model

    Journal of Pharmacy and Pharmacology

    Epilepsy is a debilitating neurological disorder that drives progressive neurodegeneration, glial activation, and disrupted neuronal signaling. Despite available therapies, drug resistance and adverse effects underscore urgent need for novel interventions. This study…

  49. Global

    Traditional Chinese medicine-derived natural products and formulations as pharmacological modulators of ageing-related pathways: mechanisms and therapeutic potential

    Journal of Pharmacy and Pharmacology

    Population ageing drives the need for interventions that extend healthspan. Ageing involves interconnected processes, including oxidative stress, mitochondrial dysfunction, chronic inflammation, metabolic dysregulation, impaired autophagy, genomic instability, proteostasis loss…

  50. Global

    Turning legislation into care: pharmacy services permitted and provided in South Africa

    International Journal of Pharmacy Practice

    The study aimed to determine the types of pharmacy services lawfully permitted to be offered and provided in the different categories of pharmacies in South Africa. A cross-sectional survey was conducted using an online self-administered questionnaire sent to all responsible…

  51. Global

    Naringenin confers neuroprotection in a cuprizone-induced mouse model of multiple sclerosis with upregulation of PPAR-γ expression

    Journal of Pharmacy and Pharmacology

    To investigate the effects of naringenin on pathological, molecular, and behavioural alterations in a cuprizone-induced mouse model of demyelination, with particular emphasis on peroxisome proliferator-activated receptor (PPAR) gamma expression, NOD-like receptor family pyrin…

  52. Global

    Activity of novel short pigment epithelium-derived factor-derived peptides in head and neck squamous cell carcinoma: effects on cell viability, metabolism, irradiation sensitivity, and mitochondrial function

    Journal of Pharmacy and Pharmacology

    Pigment epithelium-derived factor (PEDF) has anti-tumour properties mediated through distinct functional peptide domains. In this study, we investigated the biological effects of PEDF-derived peptides (coded S, V, and 44-mer) in head and neck squamous cell carcinoma (HNSCC)…